In­dia of­fers in­cen­tives to do­mes­tic drug­mak­ers for APIs; Af­ter PhI­II tri­als, Tai­ho li­cens­es Arokaris in Japan

In­dia has been de­pen­dent on the im­port of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents to man­u­fac­ture its drugs. But thanks to a a re­cent gov­ern­ment ini­tia­tive, 35 of those will now be man­u­fac­tured in the coun­try.

In­dia de­pends on im­ports for 90% of its APIs, Man­sukh Man­daviya, the Min­is­ter of Health & Fam­i­ly Wel­fare and Chem­i­cals and Fer­til­iz­ers told re­porters this week. But thanks to a pro­duc­tion-linked in­cen­tive scheme brought on by the gov­ern­ment, in-coun­try phar­mas can re­ceive pay­ments over the next six years for mak­ing for­mu­la­tions, bio­phar­ma­ceu­ti­cals, ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, key start­ing ma­te­r­i­al, drug in­ter­me­di­ates, and in vit­ro di­ag­nos­tic med­ical de­vices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.